sodium: search

Watson's Naproxen Sodium ER tabs infringes Elan's patent: US District Court

Watson Pharmaceuticals, Inc, a leading specialty pharmaceutical company, announced that the United States District Court for the Southern District of Florida ruled that Watson's Naproxen Sodium ER tablets, the generic version of Naprelan, infringes Elan's US Patent No. 5,637,320 (320 Patent). The action, Elan Corporation Plc v. Andrx Pharmaceuticals, Inc, was initially brought by Elan in October 1998 following Andrx's filing of a paragraph IV Abbreviated New Drug Application for its product.

Watson Announces District Court Ruling in Naproxen Sodium Patent Suit

CORONA, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of Florida ruled today that Watson's Naproxen Sodium ER tablets, the generic version of Naprelan(R), infringes Elan's U.S. Patent No. 5,637,320 (the "'320 Patent"). The action, Elan Corporation Plc v. Andrx Pharmaceuticals, Inc., was initially brought by Elan in October 1998 following Andrx's filing of a paragraph IV Abbreviated New Drug Application for its product. In March 2002, the District Court ruled that Elan's '320 Patent was invalid. Subsequently, in May 2004, the United States Court of Appeals for the Federal Circuit reversed the District Court's finding of invalidity and remanded the case for further proceedings.

Watson Announces District Court Ruling in Naproxen Sodium Patent Suit

CORONA, Calif., August 13, 2008 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of Florida ruled today that Watson's Naproxen Sodium ER tablets, the generic version of Naprelan(R), infringes Elan's U.S. Patent No. 5,637,320 (the "'320 Patent"). The action, Elan Corporation Plc v. Andrx Pharmaceuticals, Inc., was initially brought by Elan in October 1998 following Andrx's filing of a paragraph IV Abbreviated New Drug Application for its product. In March 2002, the District Court ruled that Elan's '320 Patent was invalid. Subsequently, in May 2004, the United States Court of Appeals for the Federal Circuit reversed the District Court's finding of invalidity and remanded the case for further proceedings.

Combination Therapy and Noninvasive Imaging With a Dual Therapeutic Vector Expressing MDR1 Short Hairpin RNA and a Sodium Iodide Symporter

Combination Therapy and Noninvasive Imaging With a Dual Therapeutic Vector Expressing MDR1 Short Hairpin RNA and a Sodium Iodide Symporter

REDUCED CALORIE FROZEN BEVERAGE [European Patents]

Inventor(s) RYAN, Sandy STATEN, Richard Title REDUCED CALORIE FROZEN BEVERAGE Abstract Disclosed herein is a reduced calorie frozen beverage and a syrup used for producing the same from a mechanical dispenser. The reduced calorie beverage of the invention provides enhanced taste and can be produced in low sodium and very low sodium versions. If you would like to purchase a copy of this patent, please call MicroPatent at 800-648-6787.

Watson Announces District Court Ruling in Naproxen Sodium Patent Suit

America's Road Home to Launch National Dialogue on Family Homelessness During the Democratic and Republican National Conventions

Watson Announces District Court Ruling in Naproxen Sodium Patent

PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. WPI, a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of

Watson Announces District Court Ruling in Naproxen Sodium Patent Suit

Hier finden Sie Nachrichten zu Ihrem Suchbegriff - Sie können den Zeitraum angeben oder auch Suchbegriffe kombinierenErweiterte Suche |

VioQuest Pharmaceuticals receives new US patent for Lenocta (sodium stibogluconate)

Broadband Service Provider Trident SR Sdn. Bhd.

Salix accuses Novel of patent infringement

Salix Pharmaceuticals has filed a patent infringement suit against Novel Laboratories for the alleged infringement of its Osmoprep (sodium biphosphate) tablets.

Elan Scores Patent Victory for Naprelan

Andrx, a subsidiary of Watson Pharmaceuticals, willfully infringed on Elan’s patent covering Naprelan, a controlled-release naproxen sodium product marketed by Victory Pharma in the U.S.

Vincent Laforet on the EOS 5D Mark II, video soon

Renowned (Pulitzer Prize-winning) photographer Vincent Laforet managed to get his hands on a Canon EOS 5D Mark II and seems to be pretty impressed with the results, "...what you can see with your eye in the worst light (such as sodium-vapor street lights at 3 a.m. in Brooklyn) - this camera can capture it with ease." However he seems even more impressed with the Mark II's video capture, "It produces the best video in low light that I’ve ever seen - at 1080p". There are a few downsampled images on his site but perhaps of more interest to many is the fact that Vincent is planning to publish a video produced using the 5D Mark II, we'll update this article once it's live.

Australian scientists find new way to store nuclear waste

Zhu Huaiyong, Associate Professor of School of Physical and Chemical Sciences, Queensland University of Technology (QUT), told Xinhua on the telephone on Friday that the research team led by him has discovered how to create nanofibres, which are millionths of a millimetre in size and can permanently lock away radioactive ions by displacing the existing sodium ions in the fibre.

Search took 0.01 seconds.